pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
zasocitinib · news · pharmadog
← back to zasocitinib
News mentioning zasocitinib
16
stories
2d
Foghorn cuts 40% of workforce
biospace
7d
6 immunology targets to sustain a mammoth I&I market
biospace
24d
Takeda’s long-term R&D head announces exit after major pipeline reorganization
biospace
25d
Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes
fiercebiotech
26d
Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics
fiercebiotech
Sep 1, 26
Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor
fiercebiotech
Aug 31, 26
FDA OKs Takeda, Protagonist drug for rare blood cancer
biopharma dive
Aug 31, 26
Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunity
biospace
Aug 10, 26
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
fiercebiotech
Aug 6, 26
Takeda’s narcolepsy nod opens orexin doors
biospace
Jul 27, 26
InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test
fiercebiotech
Jul 16, 26
Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 update
fiercebiotech
Jul 16, 26
Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial
fiercebiotech
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 11, 26
Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3
endpoints
Jun 11, 26
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
biopharma dive
